Shots:
The P-III (FRESCO-2) trial evaluating fruquintinib + BSC vs PBO + BSC in patients with metastatic CRC who had progressed on standard CT and relevant biologic agents & had progressed on, or were intolerant to TAS-102 & regorafenib at the US, EU, Japan & Australia
The trial met its 1EPs of OS & also showed an improvement in PFS. The safety profile was consistent with prior reported studies. The results will be submitted at an upcoming medical meeting
The company will discuss the results with the agencies in the US, EU, and Japan & plans to submit fruquintinib’s MAA shortly. The company also retains all commercial rights to fruquintinib outside of China & was marketed under the brand name Elunate
Ref: GlobeNewswire | Image: HUTCHMED
